Focus Partners Wealth
VKTX icon

Focus Partners Wealth’s Viking Therapeutics VKTX Stock Holding History

Focus Partners Wealth’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,767
Closed -$203K – 2844
2025
Q4 		$203K Buy
+5,767
New +$204K ﹤0.01% 2444

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Focus Partners Wealth's VKTX Position: Q1 2026 in Review

Focus Partners Wealth sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 5,767 shares — an estimated $203K sold.

Focus Partners Wealth first reported a position in VKTX in Q4 2025 and held it in 1 quarter. The position peaked at $203K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Focus Partners Wealth reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Focus Partners Wealth sold 5,767 Viking Therapeutics shares in Q1 2026, an estimated $203K.
  • Focus Partners Wealth first reported a position in Viking Therapeutics in Q4 2025 and held it in 1 quarter.
  • Focus Partners Wealth's Viking Therapeutics position peaked at $203K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.